Page last updated: 2024-11-05

ticlopidine and Gangrene

ticlopidine has been researched along with Gangrene in 3 studies

Ticlopidine: An effective inhibitor of platelet aggregation commonly used in the placement of STENTS in CORONARY ARTERIES.
ticlopidine : A thienopyridine that is 4,5,6,7-tetrahydrothieno[3,2-c]pyridine in which the hydrogen attached to the nitrogen is replaced by an o-chlorobenzyl group.

Gangrene: Death and putrefaction of tissue usually due to a loss of blood supply.

Research Excerpts

ExcerptRelevanceReference
"To assess the effect of ticlopidine on the cutaneous circulation, 25 patients with lower limb ischemia were investigated just before and at two hours after being given a 200 mg oral dose of ticlopidine."3.68Effect of ticlopidine on the cutaneous circulation in peripheral vascular disease. ( Iwai, T; Qian, S, 1993)

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's2 (66.67)18.2507
2000's0 (0.00)29.6817
2010's1 (33.33)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Fathi, R1
Shamma, HN1
Fathi, A1
Qian, S1
Iwai, T1
Tanaka, T1
Takei, M1
Fukuta, Y1
Higashino, R1
Fukuda, Y1
Nomura, Y1
Ito, S1
Tamaki, H1
Kurimoto, T1
Suzuki, Y1

Other Studies

3 other studies available for ticlopidine and Gangrene

ArticleYear
Clopidogrel-associated vasculopathic cutaneous reaction.
    Dermatology online journal, 2013, Jan-15, Volume: 19, Issue:1

    Topics: Aged; Biopsy; Clopidogrel; Fibrin; Fingers; Gangrene; Humans; Male; Platelet Aggregation Inhibitors;

2013
Effect of ticlopidine on the cutaneous circulation in peripheral vascular disease.
    Angiology, 1993, Volume: 44, Issue:8

    Topics: Aged; Blood Gas Monitoring, Transcutaneous; Drug Evaluation; Female; Gangrene; Humans; Intermittent

1993
Arachidonic acid-induced hind limb gangrene: a new experimental rat model of peripheral vascular disease.
    Biological & pharmaceutical bulletin, 1999, Volume: 22, Issue:3

    Topics: Animals; Arachidonic Acid; Aspirin; Disease Models, Animal; Disease Progression; Drug Evaluation, Pr

1999